Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Mechanism of action  




2 References  













Monalizumab






●فارسی
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Mechanism of action

[edit]

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]

References

[edit]
  1. ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  • ^ IPH2201 studies
  • ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  • ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  • ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
  • ^ van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.
    • Stub icon

    This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Monalizumab&oldid=1190942825"
    Categories: 
    ●Monoclonal antibody stubs
     ●Experimental monoclonal antibodies
     ●Monoclonal antibodies
     ●Drugs developed by AstraZeneca
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Drugs with non-standard legal status
     ●Chemicals that do not have a ChemSpider ID assigned
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
     ●Drugs that are a monoclonal antibody
     ●All stub articles
      


    ●This page was last edited on 20 December 2023, at 19:22 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki